DSGN · Design Therapeutics, Inc.
$12.02
+0.15 (+1.26%)
At close · Jul 29
Market Cap
$741.36M
Shares
62.46M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| Investor Event Transcript | 2026-06-30 | — | |
| Investor Event Transcript | 2026-06-30 | — | |
| 8-K | 2026-06-11 | 2026-06-09 | |
| 8-K | 2026-05-18 | — | |
| 8-K | 2026-04-28 | — | |
| 10-Q | 2026-04-28 | 2026-03-31 | |
| DEF 14A | 2026-04-23 | — | |
| 8-K | 2026-04-01 | 2026-03-31 | |
| 8-K | 2026-03-09 | — | |
| 10-K | 2026-03-09 | 2025-12-31 | |
| 8-K | 2026-01-30 | 2026-01-29 | |
| 10-Q | 2025-11-05 | 2025-09-30 | |
| 8-K | 2025-11-05 | — | |
| 8-K | 2025-09-10 | 2025-09-09 | |
| 8-K | 2025-08-07 | — | |
| 10-Q | 2025-08-07 | 2025-06-30 | |
| 8-K | 2025-06-12 | 2025-06-10 | |
| 10-Q | 2025-05-07 | 2025-03-31 | |
| 8-K | 2025-05-07 | — | |
| DEF 14A | 2025-04-24 | 2025-06-10 | |
| 10-K | 2025-03-10 | 2024-12-31 | |
| 8-K | 2025-03-10 | — | |
| 8-K | 2025-01-13 | — | |
| 8-K | 2024-11-07 | — | |
| 10-Q | 2024-11-07 | 2024-09-30 | |
| 8-K | 2024-08-05 | — | |
| 10-Q | 2024-08-05 | 2024-06-30 | |
| 8-K | 2024-06-17 | 2024-06-13 | |
| 8-K | 2024-05-08 | — | |
| 10-Q | 2024-05-08 | 2024-03-31 | |
| DEF 14A | 2024-04-25 | 2024-06-13 | |
| 8-K | 2024-03-19 | — | |
| 10-K | 2024-03-19 | 2023-12-31 | |
| 10-Q | 2023-11-13 | 2023-09-30 | |
| 8-K | 2023-11-13 | — | |
| 8-K | 2023-08-25 | — | |
| 8-K | 2023-08-14 | — | |
| 10-Q | 2023-08-14 | 2023-06-30 | |
| 8-K | 2023-06-01 | 2023-05-31 | |
| 8-K | 2023-05-09 | — | |
| 10-Q | 2023-05-09 | 2023-03-31 | |
| DEF 14A | 2023-04-13 | 2023-05-31 | |
| 8-K | 2023-03-14 | — | |
| 10-K | 2023-03-14 | 2022-12-31 | |
| 10-Q | 2022-11-03 | 2022-09-30 | |
| 8-K | 2022-11-03 | — | |
| 10-Q | 2022-08-08 | 2022-06-30 | |
| 8-K | 2022-08-08 | — | |
| 8-K | 2022-06-16 | 2022-06-15 | |
| 8-K | 2022-05-09 | — |
Showing 1–50 of 65 filings
Key facts
CIK
1807120
CUSIP
25056L103
13F (30d)
20 filings
20 filers
Visit website
Investor relations